UK project to reduce PFAS pollution is awarded Stockholm Junior Water Prize

27.8.2024 23:29:00 EEST | Business Wire | Press release

Christopher Whitfield and Wenqi (Jonathan) Zhao from the United Kingdom receive the prestigious Stockholm Junior Water Prize 2024 for their work on PFAS pollution in the Thames Basin. HRH Crown Princess Victoria of Sweden presented the winners with their award during a ceremony at World Water Week in Stockholm.

Per- and polyfluoroalkyl substances (PFAS) pollution is a growing concern worldwide. Focusing on the Thames Basin in the United Kingdom, where there are with no equitable solutions to the problem, Whitfield and Zhao developed a geospatial neural network, predicting PFAS values to within 10 percent of experimentally validated values.

For this, they were announced the winners of the Stockholm Junior Water Prize, an international competition where students between the ages of 15 and 20 present solutions to major water challenges.

Speaking on winning the prize, Zhao said, “We are very proud to have won this prize. It has been an amazing stay here in Sweden with so many new friends”.

The Jury noted that Whitfield and Zhao “find a way to take data and turn it into actionable knowledge. [They have] identified PFAS hotspots using machine learning, field tested their results, developed a cost-effective filtration system, and reached out to local governments and environmental organizations to raise awareness.”

The winners were presented with their prize during an award ceremony at World Water Week by HRH Crown Princess Victoria of Sweden, the Prize’s Official Patron.

The Diploma of Excellence was awarded to Shanni Valeria Mora Fajardo and Rosa Mendoza Sosa from Mexico for their work on how to reuse inked water with homemade filtration to produce veggie gardens.

The People’s Choice Award went to Manoel José Nunes Neto from Brazil, completing the line-up of winners.

The Stockholm Junior Water Prize has been organized every year since 1997. It is hosted by the Stockholm Water Foundation, with Xylem as Founding Partner.

“Innovation is paving the way to a more water-secure world, and the next generation are accelerating progress. The Stockholm Junior Water Prize competitors are an inspiring example of the ingenuity and passion young innovators bring to the table. On behalf of Xylem, I’d like to congratulate all those who took part in this year’s competition,” said Austin Alexander, Vice President of Sustainability and Social Impact at Xylem.

Read more about the winning projects:

View source version on businesswire.com: https://www.businesswire.com/news/home/20240827691002/en/

Contacts

Andreas Karlsson
Head of Communication, Stockholm International Water Institute
Email: andreas.karlsson@siwi.org, Mobile: +46 (0) 720 506078

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom